CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 108 enrolled
Drug / intervention
Citalopram +2 moredrug
Likely dose
Citalopram 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01535573
NCT01535573Phase 2Completed
CompareCT.gov

Clinical Trial of Serotonin Medication Combination in Cocaine Dependence

Joy Schmitz·interventional·Posted Feb 17, 2012·Updated Sep 16, 2020

In Brief

A Phase 2 clinical trial evaluating Citalopram and Placebo for Cocaine Dependence. Completed, enrolled 108 participants across 1 site.

Detailed Summary

This is a phase 2 clinical trial of citalopram pharmacotherapy for treatment of cocaine dependence. Using a double-blind, randomized controlled design, eligible cocaine dependent patients will be assigned equally to one of three medication conditions: placebo or the Selective serotonin re-uptake inhibitor (SSRI) agent, citalopram at either 20 mg per day or 40 mg per day. It is hypothesized that citalopram will reduce cocaine use and increase periods of sustained abstinence substantially more than placebo. Performance on a set of behavioral tasks of impulsivity will be analyzed as potential predictors of treatment response.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 17, 2012
Enrollment StartDec 1, 2010
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 14.4 years ago

Interventions

Citalopramdrug

20 mg once per day for 9 weeks

Citalopramdrug

40 mg per day for 9 weeks

Placebodrug

0 mg per day for 9 weeks